Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Clinical trial NCT04638582 · TERMINATED

Trial details

NCT number: NCT04638582
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer, Nonsmall Cell

Start date: 2022-08-28
Primary completion: 2026-04-14
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.